{"denoms":[{"counts":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"38"}],"units":"Participants"}],"groups":[{"description":"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMelphalan Hydrochloride: Given IV\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV","id":"BG000","title":"Regimen A (Fludarabine, Melphalan, PBSC HCT, GVHD Prophylaxis)"},{"description":"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nBusulfan: Given IV\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV","id":"BG001","title":"Regimen B (Fludarabine, Busulfan, PBSC HCT, GVHD Prophylaxis)"},{"description":"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.\n\nPatients undergo PBSC HCT on day 0.\n\nPatients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nHematopoietic Cell Transplantation: Undergo PBSC HCT\n\nLaboratory Biomarker Analysis: Correlative studies\n\nMycophenolate Mofetil: Given IV or PO\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSC HCT\n\nQuality-of-Life Assessment: Ancillary studies\n\nTacrolimus: Given IV\n\nTotal-Body Irradiation: Undergo TBI","id":"BG002","title":"Regimen C (Fludarabine, TBI, PBSC HCT, GVHD Prophylaxis)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"33","upperLimit":"72","value":"63"},{"groupId":"BG002","lowerLimit":"21","upperLimit":"57","value":"44"},{"groupId":"BG003","lowerLimit":"21","upperLimit":"72","value":"53"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"19"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"11"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"26"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"8"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"24"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"38"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"No subject enrolled onto Regimen B."}